Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Fig. 1

Reported efficacy of bevacizumab for HOCF by HHT centers. Bar color represents response selected by respondent (e.g. 75–100% of patients treated at their center had improvement in cardiac index and heart failure symptoms) and bar height reports the number of centers responding with that category for a given question. CI, cardiac index; HF, heart failure

Back to article page